Focus on Lipids Care

Back to articles

Cardiovascular events are lower with statins plus alirocumab

KEY POINT

Adding alirocumab (Praluent—Sanofi, Regeneron) to high-intensity statin therapy for patients who had an acute coronary syndrome (ACS) in the preceding 12 months resulted in a significantly lower risk of cardiovascular (CV) events compared with placebo, according to results of the ODYSSEY OUTCOMES trial published in the New England Journal of Medicine.

SOURCES

Schwartz GG, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Eng J Med. 2018;379(22):2097–107. 

Burnett JR, et al. PCSK9—a journey to cardiovascular outcomes. N Eng J Med. 2018; 379(22):2161–2.